Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Immunotherapy Inches Forward in Development of Myeloid Malignancies
Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.
Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myelo...
Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.
Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.
Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
Use of daratumumab for transplant-ineligible myeloma
During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.
Scientists create ON-OFF switches to control CAR T cell activity
Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.
Patient Resource: Latest News on CAR T-Cell Therapy for Multiple Myeloma
How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?
Interim results from ZUMA-12: Axi-cel as frontline treatment for high-risk LBCL
Patients with high-risk large B-cell lymphoma (LBCL) are mainly treated with rituximab-based chemoimmunotherapies that do not provide sufficient efficacy, as approximately 50% of these patients will not achieve long-term disease remission.
T-cell engaging antibodies for hematological diseases from approved therapies to...
Are bispecific antibodies less effective (and less toxic) than CAR-T cells? This educational video from the EHA25 congress shows us that the race between CAR-T therapy and bispecific Abs for hematological diseases is still ongoing!
Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review
The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.